Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107

12 Feb 2025

Abstract excerpt

Recurrent respiratory papillomatosis (RRP) is a chronic airway disease caused by Human Papillomavirus (HPV). INO-3107, DNA immunotherapy designed to elicit T-cells against HPV-6 and HPV-11, was evaluated in a 52-week Phase 1/2 study for efficacy, safety, and immunogenicity (NCT04398433). Thirty-two eligible adults with HPV-6 and/or HPV-11 RRP, requiring ≥2 surgical interventions in the year preceding dosing were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Cells and Metastasis
Share to Cervical Cancer and HPV Research
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39939590
DOI: 10.1038/s41467-025-56729-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107PMID 39939590Read ↗

DNA Immunotherapy for Recurrent Respiratory Papillomatosis (RRP): Phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107Semantic proximity Read ↗

Comprehensive multiomic characterization of human papillomavirus-driven recurrent respiratory papillomatosis reveals distinct molecular subtypesSemantic proximity Read ↗

PRGN-2012 gene therapy in adults with recurrent respiratory papillomatosis: a pivotal phase 1/2 clinical trialSemantic proximity Read ↗

Genomic diversity of HPV6 and HPV11 in recurrent respiratory papillomatosis: Association with malignant transformation in the lungs and clinical outcomes.Semantic proximity Read ↗

Clinical, virological, and immunohistochemical features of laryngeal papilloma with low-risk human papillomavirus infection: insights from a 13-year institutional cohort.Semantic proximity Read ↗

Diagnostic Accuracy of Circulating Tumor HPV DNA Testing in Patients With a Lateral Neck MassSemantic proximity Read ↗

Recurrent respiratory papillomatosis: clinical characteristics and viral genotyping in a Brazilian population.Semantic proximity Read ↗

Recurrent respiratory papillomatosis: HPV genotypes and risk of high-grade laryngeal neoplasia.Semantic proximity Read ↗

Immune Dysregulation and Tumor-Associated Gene Changes in Recurrent Respiratory Papillomatosis: A Paired Microarray AnalysisSemantic proximity Read ↗

T-cell immunity induced and reshaped by an anti-HPV immuno-oncotherapeutic lentiviral vectorSemantic proximity Read ↗

A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer RecurrenceSemantic proximity Read ↗

Role of epstein-barr virus in the severity of recurrent respiratory papillomatosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.